Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
28.58
+0.73 (2.62%)
At close: Jun 18, 2025, 4:00 PM
28.57
-0.01 (-0.03%)
After-hours: Jun 18, 2025, 7:18 PM EDT
Instil Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
187.48M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TIL News
- 8 days ago - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - GlobeNewsWire
- 17 days ago - Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 20 days ago - Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 25 days ago - Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success - Seeking Alpha
- 27 days ago - Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - GlobeNewsWire
- 4 weeks ago - Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 - GlobeNewsWire
- 5 weeks ago - Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire